Details of Drug

Drug General Information (ID: D0972)
Drug Name	Magnesium glycinate
Drug Type	Small molecule
Drug Synonymous	magnesium 2-aminoacetate; MAGNESIUM GLYCINATE; 14783-68-7; Bis(glycinato-N,O)magnesium; Magnesium diglycinate; magnesium;2-aminoacetate; UNII-IFN18A4Y6B; IFN18A4Y6B; C4H8MgN2O4; Magnesium glycinate [USAN]; EINECS 238-852-2; Glycine, magnesuim salt; SCHEMBL33936; DTXSID90163815; AMY37022; AKOS015915000; DB11189; AS-17715; Magnesium,bis(glycinato)- (6CI,7CI,8CI); FT-0656603; V1500; Q19597808 Click to Show/Hide
Therapeutic Class	Minerals And Electrolytes
Structure
Structure	3D Structure		2D Structure
Formula	C4H8MgN2O4
InChI	InChI=1S/2C2H5NO2.Mg/c23-1-2(4)5;/h21,3H2,(H,4,5);/q;;+2/p-2
InChIKey	AACACXATQSKRQG-UHFFFAOYSA-L
Canonical SMILES	C(C(=O)[O-])N.C(C(=O)[O-])N.[Mg+2]
External Link
External Link	Pubchem ID	84645

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM003 Complex formation BM059 Increased risk of hypermagnesemia BM107 Attenuated pharmacological effects (Unspecific)
Relation Graph

Full list of drugs interacting with Magnesium glycinate
Affected gastrointestinal absorption
	Complex formation					Drug Num: 26
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0515		Dolutegravir	C20H19F2N3O5	54726191	Major		Inter Info	[1]
D0181		Bictegravir	C21H18F3N3O5	90311989	Major		Inter Info	[2], [3], [4]
D0034		Alendronic acid	C4H13NO7P2	2088	Moderate		Inter Info	[6], [7], [8]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Moderate		Inter Info	[13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44]
D0433		Deferiprone	C7H9NO2	2972	Moderate		Inter Info	[45]
D0441		Demeclocycline	C21H21ClN2O8	54680690	Moderate		Inter Info	[46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [34], [56], [44]
D0530		Doxycycline	C22H24N2O8	54671203	Moderate		Inter Info	[46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [34], [56], [44]
D0561		Eltrombopag	C25H22N4O4	135449332	Moderate		Inter Info	[3], [57]
D0623		Etidronic acid	C2H8O7P2	3305	Moderate		Inter Info	[7], [58], [8]
D0712		Gatifloxacin	C19H22FN3O4	5379	Moderate		Inter Info	[26], [27], [40]
D0716		Gemifloxacin	C18H20FN5O4	9571107	Moderate		Inter Info	[13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44]
D0783		Ibandronate	C9H23NO7P2	60852	Moderate		Inter Info	[59], [60], [6], [7], [61], [8]
D0919		Levofloxacin	C18H20FN3O4	149096	Moderate		Inter Info	[13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44]
D0144		Baloxavir marboxil	C27H23F2N3O7S	124081896	Moderate		Inter Info	[62]
D0438		Delafloxacin	C18H12ClF3N4O4	487101	Moderate		Inter Info	[13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44]
D1175		Omadacycline	C29H40N4O7	54697325	Moderate		Inter Info	[49], [52], [56]
D1445		Sarecycline	C24H29N3O8	54681908	Moderate		Inter Info	[46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [34], [56], [44]
D1070		Minocycline	C23H27N3O7	54675783	Moderate		Inter Info	[46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [34], [56], [44]
D1092		Moxifloxacin	C21H24FN3O4	152946	Moderate		Inter Info	[13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44]
D1155		Norfloxacin	C16H18FN3O3	4539	Moderate		Inter Info	[26], [27], [40]
D1165		Ofloxacin	C18H20FN3O4	4583	Moderate		Inter Info	[13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44]
D1245		Penicillamine	C5H11NO2S	5852	Moderate		Inter Info	[63], [64], [65], [66], [67], [68], [69], [34]
D1377		Raltegravir	C20H21FN6O5	54671008	Moderate		Inter Info	[70], [2], [3], [71], [72], [73]
D1412		Risedronic acid	C7H11NO7P2	5245	Moderate		Inter Info	[6], [7], [8]
D1564		Tetracycline	C22H24N2O8	54675776	Moderate		Inter Info	[46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [34], [56], [44]
D1657		Trovafloxacin	C20H15F3N4O3	62959	Moderate		Inter Info	[26], [27], [40]
Pharmacodynamic additive effects
	Increased risk of hypermagnesemia					Drug Num: 8
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0233		Calcifediol	C27H44O2	5283731	Moderate		Inter Info	[9], [10], [11], [12]
D0234		Calcitriol	C27H44O3	5280453	Moderate		Inter Info	[9], [10], [11], [12]
D0328		Cholecalciferol	C27H44O	5280795	Moderate		Inter Info	[9], [10], [11], [12]
D0527		Doxercalciferol	C28H44O2	5281107	Moderate		Inter Info	[9], [10], [11], [12]
D0591		Ergocalciferol	C28H44O	5280793	Moderate		Inter Info	[9], [10], [11], [12]
D0968		Magnesium carbonate	CMgO3	11029	Moderate		Inter Info	[3]
D0973		Magnesium hydroxide	H2MgO2	14791	Moderate		Inter Info	[3]
D1226		Paricalcitol	C27H44O3	5281104	Moderate		Inter Info	[9], [10], [11], [12]
Pharmacodynamic antagonistic effects
	Attenuated pharmacological effects (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0590		Erdafitinib	C25H30N6O2	67462786	Major		Inter Info	[5]

References
1	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
2	Cerner Multum, Inc. "Australian Product Information.".
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4	Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir). Gilead Sciences, Foster City, CA.
5	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
6	Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
7	Product Information. Boniva (ibandronate). Roche Laboratories, Nutley, NJ.
8	Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
9	Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
10	Product Information. One-Alpha (alfacalcidol). Pharmel Inc, Montreal, IN.
11	Product Information. Rocaltrol (calcitriol). Roche Laboratories, Nutley, NJ.
12	Product Information. Zemplar (paricalcitol). Abbott Pharmaceutical, Abbott Park, IL.
13	Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
14	Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11. [PMID: 10567782]
15	Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6. [PMID: 1540482]
16	Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2. [PMID: 1503446]
17	Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3. [PMID: 2360833]
18	Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7. [PMID: 2751276]
19	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
20	Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58. [PMID: 9916608]
21	Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103. [PMID: 10671902]
22	Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82. [PMID: 7955811]
23	Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51. [PMID: 8192452]
24	Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71. [PMID: 10223915]
25	Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5. [PMID: 2598571]
26	Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
27	Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9. [PMID: 3382110]
28	Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102. [PMID: 2712548]
29	Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4. [PMID: 2610494]
30	Product Information. Baxdela (delafloxacin). Melinta Therapeutics, Lincolnshire, IL.
31	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
32	Product Information. Levaquin (levofloxacin). Ortho Pharmaceutical Corporation, Raritan, NJ.
33	Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
34	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
35	Product Information. Trovan (trovafloxacin). Pfizer US Pharmaceuticals, New York, NY.
36	Product Information. Zagam (sparfloxacin). Rhone-Poulenc Rorer, Collegeville, PA.
37	Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4. [PMID: 8471407]
38	Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24. [PMID: 1329615]
39	Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6. [PMID: 8820479]
40	Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7. [PMID: 9222077]
41	Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60. [PMID: 1724637]
42	Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901. [PMID: 2754785]
43	Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72. [PMID: 9257738]
44	Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7. [PMID: 2610502]
45	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
46	Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
47	D'Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17. [PMID: 2886325]
48	Garty M, Hurwitz A "Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline." Clin Pharmacol Ther 28 (1980): 203-7. [PMID: 7398187]
49	Gotz VP, Ryerson GG "Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease." Drug Intell Clin Pharm 20 (1986): 694-6. [PMID: 3757782]
50	McCormack JP, Reid SE, Lawson LM "Theophylline toxicity induced by tetracycline." Clin Pharm 9 (1990): 546-9. [PMID: 2376112]
51	Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54. [PMID: 946598]
52	Nguyen VX, Nix DE, Gillikin S, Schentag JJ "Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline." Antimicrob Agents Chemother 33 (1989): 434-6. [PMID: 2729939]
53	Product Information. Declomycin (demeclocycline). Lederle Laboratories, Wayne, NJ.
54	Product Information. Nuzyra (omadacycline). Paratek Pharmaceuticals, Inc., Boston, MA.
55	Product Information. Seysara (sarecycline). Allergan Inc, Irvine, CA.
56	Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part I)." Clin Pharmacokinet 20 (1991): 66-80. [PMID: 1674242]
57	Product Information. Promacta (eltrombopag). GlaxoSmithKline, Research Triangle Park, NC.
58	Product Information. Fosamax (alendronate). Merck &amp Co, Inc, West Point, PA.
59	Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54. [PMID: 8845456]
60	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
61	Product Information. Fosamax (alendronate). Merck & Co, Inc, West Point, PA.
62	Product Information. Xofluza (baloxavir marboxil). Genentech, South San Francisco, CA.
63	Haagsma CJ "Clinically important drug interactions with disease-modifying antirheumatic drugs." Drugs Aging 13 (1998): 281-9. [PMID: 9805209]
64	Harkness JA, Blake DR "Penicillamine nephropathy and iron." Lancet 2 (1982): 1368-9. [PMID: 6129465]
65	Joyce DA "D-penicillamine pharmacokinetics and pharmacodynamics in man." Pharmacol Ther 42 (1989): 405-27. [PMID: 2672052]
66	Lyle WH "Penicillamine and iron." Lancet 2 (1976): 420. [PMID: 73880]
67	Netter P, Bannwarth B, Pere P, Nicolas A "Clinical pharmacokinetics of D-penicillamine." Clin Pharmacokinet 13 (1987): 317-33. [PMID: 3319347]
68	Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG "Reduction in oral penicillamine absorption by food, antacid and ferrous sulfate." Clin Pharmacol Ther 33 (1983): 465-70. [PMID: 6831825]
69	Product Information. Cuprimine (penicillamine). Merck & Co, Inc, West Point, PA.
70	Canadian Pharmacists Association.
71	Kiser JJ, Bumpass JB, Meditz AL, et al. "Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus seronegative volunteers." Antimicrob Agents Chemother 54 (2010): 4999-5003. [PMID: 20921313]
72	Moss DM, Siccardi M, Murphy M, et al. "Divalent metals and pH alter raltegravir disposition in vitro." Antimicrob Agents Chemother 56 (2012): 3020-6. [PMID: 22450971]
73	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence